X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13027) 13027
Publication (1124) 1124
Book Chapter (193) 193
Book Review (127) 127
Newsletter (87) 87
Conference Proceeding (39) 39
Newspaper Article (36) 36
Dissertation (32) 32
Magazine Article (23) 23
Reference (19) 19
Book / eBook (5) 5
Streaming Video (2) 2
Web Resource (2) 2
Data Set (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7107) 7107
animals (5418) 5418
male (4694) 4694
index medicus (4157) 4157
female (3386) 3386
aldosterone (3118) 3118
rats (2746) 2746
mineralocorticoid receptor (2658) 2658
mineralocorticoid receptor antagonists - therapeutic use (2133) 2133
endocrinology & metabolism (2080) 2080
hypertension (1797) 1797
spironolactone (1678) 1678
mineralocorticoid receptor antagonists (1579) 1579
middle aged (1523) 1523
adult (1495) 1495
receptors, mineralocorticoid - metabolism (1456) 1456
spironolactone - therapeutic use (1217) 1217
mineralocorticoids (1199) 1199
corticosteroids (1182) 1182
mineralocorticoid receptor antagonists - pharmacology (1105) 1105
aged (1102) 1102
spironolactone - pharmacology (1091) 1091
neurosciences (1089) 1089
steroids (1071) 1071
cardiac & cardiovascular systems (1052) 1052
peripheral vascular disease (1048) 1048
mice (979) 979
heart failure (962) 962
heart failure - drug therapy (932) 932
aldosterone - metabolism (900) 900
spironolactone - analogs & derivatives (872) 872
aldosterone - pharmacology (871) 871
receptors, mineralocorticoid - genetics (868) 868
blood-pressure (853) 853
glucocorticoid receptor (845) 845
biochemistry & molecular biology (844) 844
pharmacology & pharmacy (837) 837
receptors, glucocorticoid - metabolism (832) 832
physiology (809) 809
corticosterone (778) 778
eplerenone (774) 774
rats, sprague-dawley (744) 744
expression (734) 734
angiotensin-converting enzyme inhibitors - therapeutic use (725) 725
stress (719) 719
brain (710) 710
aldosterone - blood (704) 704
blood pressure - drug effects (704) 704
treatment outcome (700) 700
glucocorticoids (691) 691
hypertension - drug therapy (676) 676
blood pressure (675) 675
hypertension - physiopathology (657) 657
adrenalectomy (656) 656
cortisol (652) 652
mineralocorticoid receptors (636) 636
angiotensin-ii (627) 627
urology & nephrology (625) 625
time factors (612) 612
research (610) 610
rats, wistar (600) 600
heart-failure (596) 596
oxidative stress (565) 565
apparent mineralocorticoid excess (564) 564
mineralocorticoids - metabolism (559) 559
mortality (553) 553
hippocampus (545) 545
mineralocorticoid (542) 542
risk factors (524) 524
analysis (523) 523
receptors, mineralocorticoid - physiology (523) 523
medicine, general & internal (518) 518
aldosterone - physiology (515) 515
gene-expression (512) 512
sodium - metabolism (499) 499
physiological aspects (498) 498
dose-response relationship, drug (483) 483
kidney - metabolism (483) 483
cell biology (474) 474
hypertension - etiology (472) 472
renin - blood (471) 471
article (470) 470
mineralocorticoid receptor antagonists - administration & dosage (464) 464
receptors, glucocorticoid - genetics (463) 463
mineralocorticoid receptor antagonists - adverse effects (462) 462
adolescent (456) 456
drug therapy, combination (448) 448
rat (447) 447
cells, cultured (445) 445
fibrosis (441) 441
rna, messenger - metabolism (439) 439
11-beta-hydroxysteroid dehydrogenase (435) 435
disease models, animal (431) 431
gene expression (430) 430
heart failure - physiopathology (426) 426
kidney (416) 416
myocardial-infarction (411) 411
receptors, mineralocorticoid (411) 411
abridged index medicus (410) 410
adrenergic beta-antagonists - therapeutic use (405) 405
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11926) 11926
German (355) 355
French (341) 341
Japanese (268) 268
Russian (194) 194
Italian (116) 116
Spanish (109) 109
Polish (34) 34
Czech (26) 26
Danish (26) 26
Hungarian (23) 23
Chinese (22) 22
Portuguese (22) 22
Dutch (18) 18
Korean (12) 12
Bulgarian (8) 8
Swedish (5) 5
Ukrainian (5) 5
Norwegian (4) 4
Turkish (3) 3
Croatian (2) 2
Finnish (2) 2
Lithuanian (2) 2
Bosnian (1) 1
Icelandic (1) 1
Romanian (1) 1
Serbian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Trends in Endocrinology & Metabolism, ISSN 1043-2760, 2015, Volume 26, Issue 4, pp. 201 - 211
Highlights • Mineralocorticoid receptor (MR) antagonists have proven benefits in hypertension and heart failure. • Atrial fibrillation (AF), pulmonary... 
Endocrinology & Metabolism | novel indications | mineralocorticoid receptor | spironolactone | eplerenone | Eplerenone | Spironolactone | Mineralocorticoid receptor | Novel indications | CHRONIC HEART-FAILURE | ALDOSTERONE ANTAGONISTS | MYOCARDIAL-INFARCTION | PLASMA-ALDOSTERONE | LEFT-VENTRICULAR HYPERTROPHY | ANTI-ALDOSTERONE | ATRIAL-FIBRILLATION | RENIN-ANGIOTENSIN SYSTEM | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | STAGE RENAL-DISEASE | Severity of Illness Index | Arrhythmias, Cardiac - prevention & control | Receptors, Mineralocorticoid - agonists | Cardiovascular Diseases - physiopathology | Off-Label Use | Cardiovascular Diseases - metabolism | Receptors, Mineralocorticoid - metabolism | Cardiovascular Diseases - drug therapy | Humans | Death, Sudden, Cardiac - prevention & control | Arrhythmias, Cardiac - etiology | Death, Sudden, Cardiac - etiology | Disease Progression | Hypertension, Pulmonary - prevention & control | Mineralocorticoid Receptor Antagonists - therapeutic use | Heart Failure - prevention & control | Cardiovascular Agents - therapeutic use | Animals | Models, Biological | Heart Failure - etiology | Hypertension, Pulmonary - etiology | Receptors, Mineralocorticoid - chemistry | Heart failure | Hypertension | Heart | Hospitals | Atrial fibrillation | Steroids | Cardiovascular Diseases | Receptors, Mineralocorticoid | Hypertension, Pulmonary | Arrhythmias, Cardiac | Cardiovascular Agents | Death, Sudden, Cardiac | Life Sciences | Human health and pathology | Heart Failure | Mineralocorticoid Receptor Antagonists | Cardiology and cardiovascular system
Journal Article
Hypertension, ISSN 0194-911X, 04/2018, Volume 71, Issue 4, pp. 609 - 621
Stiffening of the vasculature with aging is a strong predictor of adverse cardiovascular events, independent of all other risk factors including blood... 
Receptors | Gene expression profiling | Mineralocorticoid | Smooth muscle | Blood pressure | Myocytes | Vascular stiffening | blood pressure | receptors | HEART-FAILURE | smooth muscle | ANGIOTENSIN-II | AORTIC STIFFNESS | myocytes | mineralocorticoid | vascular stiffening | ARTERIAL STIFFNESS | DISEASE | VASCULAR INFLAMMATION | PERIPHERAL VASCULAR DISEASE | ALDOSTERONE | CARDIAC FIBROSIS | gene expression profiling | MOLECULAR-MECHANISMS | GENE-TRANSCRIPTION | Receptors, Mineralocorticoid - genetics | Gene Expression - drug effects | Muscle, Smooth, Vascular - metabolism | Receptors, Mineralocorticoid - metabolism | Humans | Cellular Senescence - drug effects | Male | Gene Expression Profiling | Spironolactone - metabolism | Fibrosis - metabolism | Mineralocorticoid Receptor Antagonists - metabolism | Spironolactone - pharmacology | Mineralocorticoid Receptor Antagonists - pharmacology | Fibrosis - prevention & control | Myocytes, Smooth Muscle - drug effects | Myocytes, Smooth Muscle - metabolism | Muscle, Smooth, Vascular - drug effects | Cellular Senescence - physiology | Treatment Outcome | Disease Progression | Muscle, Smooth, Vascular - pathology | Animals | Exercise Tolerance - physiology | Vascular Stiffness - drug effects | Vascular Stiffness - physiology | Aged | Mice | Fibrosis - pathology | Hormone receptors | Care and treatment | Fibrosis | Aging | Physiological aspects | Mineralocorticoids | Development and progression | Health aspects | Heart diseases | mineralocorticoid receptors | smooth muscle cell | aging | vascular fibrosis
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 04/2016, Volume 133, Issue 14, pp. 1360 - 1370
BACKGROUND—The hypertensive syndrome of Apparent Mineralocorticoid Excess is caused by loss-of-function mutations in the gene encoding 11β-hydroxysteroid... 
pressoreceptors | salt | solitary nucleus | mineralocorticoids | aldosterone | APPARENT MINERALOCORTICOID EXCESS | CARDIAC & CARDIOVASCULAR SYSTEMS | SODIUM APPETITE | BAROREFLEX SENSITIVITY | DISTAL TUBULE | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-2 | HEART-FAILURE | INTRACEREBROVENTRICULAR INFUSION | BLOOD-PRESSURE | PERIPHERAL VASCULAR DISEASE | MICE | Mineralocorticoid Excess Syndrome, Apparent - drug therapy | Mineralocorticoid Excess Syndrome, Apparent - genetics | Nerve Tissue Proteins - deficiency | Solitary Nucleus - enzymology | Receptors, Mineralocorticoid - physiology | RNA, Messenger - biosynthesis | Nephrons - physiopathology | Dexamethasone - pharmacology | Spironolactone - pharmacology | Reflex, Abnormal | Nestin - genetics | Neurons - physiology | Mineralocorticoid Excess Syndrome, Apparent - physiopathology | Craving - physiology | Corticosterone - blood | Hypertension - genetics | 11-beta-Hydroxysteroid Dehydrogenase Type 2 - genetics | Solitary Nucleus - physiopathology | Nerve Tissue Proteins - physiology | Mice, Inbred C57BL | Genes, Synthetic | Nerve Tissue Proteins - genetics | Hypertension - physiopathology | Drinking Behavior | Mice, Knockout | Mineralocorticoid Receptor Antagonists - therapeutic use | Baroreflex - drug effects | Animals | Sodium Chloride, Dietary - toxicity | Potassium - urine | 11-beta-Hydroxysteroid Dehydrogenase Type 2 - metabolism | 11-beta-Hydroxysteroid Dehydrogenase Type 2 - physiology | Mice | Hypertension | Measurement | Care and treatment | Phenylephrine | Blood pressure | Dosage and administration | Cardiovascular diseases | 10111 | 10014 | 10058 | Original
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 08/2015, Volume 761, pp. 226 - 234
The present study was designed to characterize the pharmacological profile of CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist. In the... 
CS-3150 | Aldosterone | Urinary Na+/K+ ratio | Mineralocorticoid receptor antagonist | Urinary Na | ratio | TARGET | OXIDATIVE STRESS | DIABETIC-NEPHROPATHY | MESSENGER-RNA | PHARMACOKINETICS | SPIRONOLACTONE | INFLAMMATION | ALDOSTERONE BLOCKER | PHARMACOLOGY & PHARMACY | HYPERTENSION | EPLERENONE | Receptors, Mineralocorticoid - genetics | Urological Agents - pharmacology | Antihypertensive Agents - pharmacology | Pyrroles - pharmacokinetics | Receptors, Mineralocorticoid - metabolism | Humans | Transcriptional Activation - drug effects | Rats, Inbred WKY | Desoxycorticosterone Acetate | Male | Water-Electrolyte Balance - drug effects | Spironolactone - metabolism | Sulfones - pharmacology | Dose-Response Relationship, Drug | Receptors, Mineralocorticoid - drug effects | Aldosterone - metabolism | Spironolactone - pharmacology | Transfection | Sodium - urine | Pyrroles - administration & dosage | Hypertension - chemically induced | HEK293 Cells | Mineralocorticoid Receptor Antagonists - pharmacology | Hypertension - prevention & control | Female | Blood Pressure - drug effects | Radioligand Assay | Spironolactone - analogs & derivatives | Disease Models, Animal | Binding, Competitive | Mineralocorticoid Receptor Antagonists - administration & dosage | Rabbits | Administration, Oral | Aldosterone - pharmacology | Sulfones - pharmacokinetics | Rats, Sprague-Dawley | Hypertension - physiopathology | Adrenalectomy | Pyrroles - pharmacology | Animals | Eplerenone | Potassium - urine | Protein Binding | Mineralocorticoid Receptor Antagonists - pharmacokinetics | Sulfones - administration & dosage | Hypertension | Hormones, Sex | Corticosteroids | Drug discovery | Spironolactone
Journal Article
Arteriosclerosis, Thrombosis, and Vascular Biology, ISSN 1079-5642, 02/2014, Volume 34, Issue 2, pp. 355 - 364
OBJECTIVE—Vascular remodeling occurs after endothelial injury, resulting in smooth muscle cell (SMC) proliferation and vascular fibrosis. We previously... 
placental growth factor | receptors mineralocorticoid | vascular endothelial growth factor receptor-1 | aldosterone | myocytes smooth muscle | MORTALITY | OXIDATIVE STRESS | EVENTS | receptors | smooth muscle | myocytes | mineralocorticoid | BLOOD-PRESSURE | SPIRONOLACTONE | PERIPHERAL VASCULAR DISEASE | EPLERENONE | HYPERTENSION | HEMATOLOGY | EXPRESSION | BLOCKER | GENE-TRANSCRIPTION | Carotid Arteries - drug effects | Carotid Arteries - metabolism | Receptors, Mineralocorticoid - agonists | Receptors, Mineralocorticoid - genetics | Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors | Muscle, Smooth, Vascular - metabolism | Pregnancy Proteins - genetics | Myocytes, Smooth Muscle - pathology | Male | Pregnancy Proteins - metabolism | RNA, Messenger - metabolism | Receptors, Mineralocorticoid - deficiency | Time Factors | Carotid Artery Injuries - genetics | Myocytes, Smooth Muscle - drug effects | Myocytes, Smooth Muscle - metabolism | Carotid Artery Injuries - metabolism | Carotid Artery Injuries - pathology | Disease Models, Animal | Muscle, Smooth, Vascular - drug effects | Endothelial Cells - metabolism | Mice, Inbred C57BL | Aldosterone - pharmacology | Vascular Endothelial Growth Factor Receptor-1 - metabolism | Mice, Knockout | Antibodies - pharmacology | Muscle, Smooth, Vascular - pathology | Animals | Fibrosis | Placenta Growth Factor | Carotid Arteries - pathology | Cell Proliferation - drug effects | Mice | Endothelial Cells - pathology | Endothelial Cells - drug effects | smooth muscle cells | mineralocorticoid receptor | vascular remodeling | VEGF
Journal Article
Journal Article
Journal of Psychopharmacology, ISSN 0269-8811, 12/2013, Volume 27, Issue 12, pp. 1169 - 1179
Background: Treatment-resistant depression patients show both reduced glucocorticoid receptor function and a hyperactive hypothalamic-pituitary-adrenal axis.... 
hypothalamic-pituitary-adrenal axis | prednisolone | Cortisol | mineralocorticoid receptor | treatment resistant depression | mineralocorticoid receptor antagonist | PSYCHIATRY | PREDNISOLONE SUPPRESSION TEST | HUMANS | CHILDHOOD EXPERIENCE | MAJOR DEPRESSION | NEUROSCIENCES | CLINICAL NEUROLOGY | CANRENOATE | GLUCOCORTICOID-RECEPTOR | PHARMACOLOGY & PHARMACY | HPA AXIS | PITUITARY-ADRENAL AXIS | BRAIN | Single-Blind Method | Mineralocorticoid Receptor Antagonists - administration & dosage | Prednisolone - administration & dosage | Spironolactone - administration & dosage | Pituitary-Adrenal System - metabolism | Receptors, Mineralocorticoid - metabolism | Humans | Middle Aged | Hydrocortisone - metabolism | Male | Receptors, Glucocorticoid - metabolism | Saliva - chemistry | Prednisolone - pharmacology | Case-Control Studies | Hypothalamo-Hypophyseal System - metabolism | Spironolactone - pharmacokinetics | Depressive Disorder, Treatment-Resistant - physiopathology | Receptors, Mineralocorticoid - drug effects | Spironolactone - pharmacology | Canrenone - metabolism | Mineralocorticoid Receptor Antagonists - pharmacology | Female | Receptors, Glucocorticoid - drug effects | Mineralocorticoid Receptor Antagonists - pharmacokinetics | Physiological aspects | Mineralocorticoids | Hypothalamic-pituitary-adrenal axis | Care and treatment | Research | Depression, Mental
Journal Article
The FASEB Journal, ISSN 0892-6638, 08/2014, Volume 28, Issue 8, pp. 3745 - 3757
The mineralocorticoid receptor (MR) controls adipocyte function, but its role in the conversion of white adipose tissue (WAT) into thermogenic fat has not been... 
metabolic syndrome | uncoupling protein 1 | UCP1 | adipogenesis | aldosterone | obesity | Obesity | Aldosterone | Metabolic syndrome | Uncoupling protein 1 | Adipogenesis | BIOCHEMISTRY & MOLECULAR BIOLOGY | MOUSE | ADULT HUMANS | ORGAN | CELL BIOLOGY | GLUCOSE-HOMEOSTASIS | IN-VIVO | BIOLOGY | GENE-EXPRESSION | DIFFERENTIATION | Inguinal Canal | Obesity - drug therapy | Adipogenesis - drug effects | Diet, High-Fat - adverse effects | Ion Channels - genetics | Adipocytes - cytology | Androstenes - pharmacology | Gene Expression Profiling | Mitochondrial Proteins - genetics | Adipocytes - drug effects | Autophagy - drug effects | Adipogenesis - physiology | Receptors, Mineralocorticoid - physiology | Receptors, Mineralocorticoid - drug effects | Glucose Intolerance - prevention & control | Spironolactone - pharmacology | Body Composition - drug effects | Glucose Intolerance - etiology | Cell Transdifferentiation - drug effects | Mineralocorticoid Receptor Antagonists - pharmacology | Macrolides - pharmacology | Female | Weight Gain - drug effects | Intra-Abdominal Fat - drug effects | Spironolactone - therapeutic use | Ion Channels - biosynthesis | Mice, Inbred C57BL | Cells, Cultured | Androstenes - therapeutic use | Aldosterone - pharmacology | Obesity - physiopathology | Mitochondrial Proteins - biosynthesis | Mineralocorticoid Receptor Antagonists - therapeutic use | Up-Regulation - drug effects | Animals | Obesity - prevention & control | Adipose Tissue, Brown - metabolism | Mice | Uncoupling Protein 1 | Adipose Tissue, White - drug effects
Journal Article
Journal of Neuroendocrinology, ISSN 0953-8194, 08/2016, Volume 28, Issue 8, pp. np - n/a
Journal Article